Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats.
Functionality of the endogenous cannabinoid system undergoes relevant changes in reward-related brain areas in animal models of opiate addiction. By using a limited access heroin self-administration paradigm we show that cannabinoid CB(1) receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716A, 0.03-3.0 mg/kg) suppresses heroin self-administration only in opiate-dependent rats but not in non-dependent animals. These results further support the study of cannabinoid CB(1) receptor antagonists for the treatment of opiate addiction.
Navarro
Miguel
M
Instituto Complutense de Drogodependencias, Departamento de Psicobiología, Facultad de Psicología, Universidad Complutense de Madrid, Spain. mnavarro@psi.ucm.es
Carrera
M Rocio A
MR
Del Arco
Ignacio
I
Trigo
Jose Manuel
JM
Koob
George F
GF
Rodríguez de Fonseca
Fernando
F
D000818:Animals; D063387:Cannabinoid Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D003932:Heroin / Q000008:administration & dosage* / Q000037:antagonists & inhibitors*; D006556:Heroin Dependence / Q000188:drug therapy*; D008297:Male; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D043882:Receptors, Cannabinoid / Q000502:physiology; D000077285:Rimonabant; D012646:Self Administration
D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D003932:Heroin; D000077285:Rimonabant